Table 3.

Therapeutic evaluation according to KIT mutation with AML1::ETO in TARGET

	AML1::ETO with KIT mutation	AML1::ETO without KIT mutation	P value
Course 1
Bone marrow			0.81
CR	78.6% (22/28)	80.6% (79/98)
Not CR	21.4% (6/28)	19.4% (19/98)
MRD			0.48
Yes	30.0% (6/20)	19.4% (14/72)
No	70.0% (14/20)	80.6% (58/72)
Course 2
Bone marrow			0.95
CR	96.4% (27/28)	93.8% (91/97)
Not CR	3.6% (1/28)	6.2% (6/97)
MRD			0.77
Yes	5.0% (1/20)	10.4% (7/67)
No	95.0% (19/20)	89.6% (60/67)

P values were analyzed by the Chi-Square Test, compared with AML1::ETO and KIT mutation group

CR Complete remission, MRD Minimal residual disease